To the Editor:
Two-Dimensional Echocardiographic Identification of Papillary Muscles
To the Editor:
The recent committee report on two-dimensional echocardiographic nomenclature' refers to the two left ventricular papillary muscles as medial and lateral when viewed in the standard shortaxis plane. Considerable confusion exists as to which of these represents the papillary muscle seen in the standard long-axis view. The excellent article by Tajik et al.,2 which focuses on the anatomic correlates of two-dimensional echocardiographic planes, identifies the papillary muscle seen in the long-axis view as the one positioned medially in the short-axis section (their figures 6 and 9). Figure 1 depicts single frames obtained from the two-dimensional examination of a patient with hypertrophic obstructive cardiomyopathy whose papillary muscles were markedly unequal in size. In the long-axis view, the papillary muscle arising from the left ventricular "posterior" wall appears enlarged. When the transducer was slowly rotated 900 to obtain the short-axis view, keeping this hypertrophied papillary muscle constantly in view, it was evident that this muscle was positioned in the short-axis section laterally, and not medially, as Tajik et al. concluded. The smaller medial papillary muscle corresponds to the papillary muscle arising from the inferior (diaphragmatic) wall of the left ventricle in the apical two-chamber view.
Our echo-autopsy correlations in other patients with papillary muscles of unequal size or markedly differing echo brightness due to the presence of fibrotic or calcific areas further support our findings. The same conclusion is reached if one inspects normal heart specimens and correlates them with transducer positions. Therefore, it appears that the identification of the papillary muscles as suggested by the Mayo Clinic group is erroneous. suaded that the statistical issue warrants the concerns expressed in the extended consideration in the editorial of the two-population model. On the other hand, at the practical level, the t test for mean differences usually yields conclusions consistent with those from a more exact analysis.' In the analysis of large bodies of data it has the advantage of being cheaper and less time-consuming than a logistic analysis. This is particularly attractive when a large number of variables must be considered. However, when an examination of the mean differences suggested a potentially significant association, we confirmed it with a logistic analysis, as the editorial noted.
Uniformly, the conclusions were the same by both methods.
It is true that the logistic function assumes monotonicity of risk over the independent variables." As was noted in the editorial, sample data for the key diet variables were presented in our paper. The trends were "not easily discernible," but nothing about the data would suggest we reject the assumption of monotonicity. However, the possibility does exist that some diet variables found to have insignificant relations when examined by our methods are, in fact, related to the incidence of coronary heart disease or death. Beyond these statistical issues, however, it must be conceded that in some instances the biologic facts may be more complicated. Thus, it is possible that persons consuming large quantities of alcohol on a regular basis may be at greater risk of developing coronary heart disease than moderate drinkers, as one study suggests. ' ' demonstrated that naloxone administration before sleep prevented the decrease in systolic pressure that is normally seen during the second cycle of deep sleep. This effect of naloxone was delayed, becoming manifest more than 140 minutes after drug infusion. The mechanism of naloxone's action on the blood pressure may be mediated through naloxone-induced release of endogenous vasopressin.
Both apomorphine and naloxone block the morphine-induced increases in serum prolactin,' and the time course of effect of naloxone on preventing the blood pressure decrease during sleep coincides with its effect on prolactin release, maximal at 180 minutes.8 Apomorphine is a potent dopamine-receptor stimulant, and some of the morphine withdrawal signs have been linked to an increased stimulation of dopamine receptors. The finding that naloxone's hypertensive effect is delayed by more than 2 hours suggests that the control it exerts on blood pressure is indirect. Plasma vasopressin has been demonstrated to be responsible for long-term blood pressure maintenance in rat and dog.' Apomorphine induces vasopressin release and its action can be blocked by haloperidol, which also blocks naloxone-induced withdrawal reaction, and so, possibly, naloxone's delayed hypertensive effect may be mediated through vasopressin release. Although Lightman et al. proposed that naloxone may block or exert no effect on vasopressin release,0' 11 it is noteworthy that in these two studies, nal'oxone was used at very low doses (0.08-0.12 mg/min) administered by slow infusion over a protracted period (40-120 minutes), and was not associated with a delayed hypertensive effect. In contrast, the studies demonstrating a delayed effect on blood pressure and elevation in plasma vasopressin used much larger doses (14-20 mg), administered in bolus form.1 8 Because some signs of opioid withdrawal have been attributed to an increase, and others a decrease, in dopaminergic activity,6 naloxone's effect L von Doenhoff and N C Nanda Two-dimensional echocardiographic identification of papillary muscles.
